Gastrointestinal Cancer | Specialty

Everolimus Approved in Europe for GI, Lung NETS

June 2nd 2016

The European Commission has approved everolimus (Afinitor) for use as treatment for patients with progressive, unresectable or metastatic, well-differentiated nonfunctional gastrointestinal or lung neuroendocrine tumors.

Expert Shares Significance of Approved Agents in CRC

June 2nd 2016

Tanios Bekaii-Saab, MD, discusses the use of both regorafenib and TAS-102, as well as the potential role immunotherapy could have within colorectal cancer.

Polyp Mutations May Hold Key to CRC Prevention

May 31st 2016

Precancerous colon polyps exhibit many of the same driver mutations that fuel the development of colorectal cancer.

New Paradigm Emerging in Advanced Pancreatic Cancer

May 25th 2016

The majority of patients with pancreatic adenocarcinoma are diagnosed with late-stage, unresectable tumors, a setting in which combination chemotherapy remains the mainstay.

Dr. Shah on the HELOISE Study for Gastric Cancer

May 20th 2016

Manish A. Shah, MD, associate professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Bartlett Family Associate Professor in Gastrointestinal Oncology, medical oncologist, Weill Cornell Medicine and New-York Presbyterian Hospital, discusses the phase IIIb HELOISE trial, which compared 2 dose regimens of trastuzumab combined with chemotherapy as a first-line treatment for patients with HER2-positive metastatic gastric/gastroesophageal junction adenocarcinoma (mGC/GEJC).

Tumor Location Linked to Survival Outcomes in Metastatic Colorectal Cancer

May 19th 2016

Survival outcomes in patients with metastatic colorectal cancer were significantly longer among those with tumors originating on the left versus the right side of the colon, according to a retrospective analysis of the phase III 80405 trial.

Phase III Olaparib Trial Misses OS Endpoint in Gastric Cancer

May 18th 2016

A phase III study exploring the combination of olaparib and paclitaxel missed its primary endpoint of improvement in overall survival compared with paclitaxel and placebo for patients with advanced gastric cancer.

Combined Vaccines Study Misses Primary Endpoint in Pancreatic Cancer

May 16th 2016

A regimen combining the vaccines CRS-207 and GVAX Pancreas failed to improve overall survival versus either CRS-207 alone or chemotherapy in patients with metastatic pancreatic cancer who had failed at least 2 prior therapies.

Pancreatic Cancer Vaccine Falls Short in Phase III Trial

May 10th 2016

The investigational pancreatic cancer vaccine algenpantucel-L failed to improve overall survival versus standard of care in the phase III IMPRESS trial.

Doxorubicin-Loaded Nanoparticle Formulation in Patients With HCC

May 6th 2016

Graham Dixon, PhD, chief scientific officer, Onxeo, discusses a mechanistic study of the relative cytotoxicity of doxorubicin-loaded nanoparticle formulation versus doxorubicin in hepatocellular carcinoma cell lines.

Regorafenib Improves Survival in Liver Cancer

May 4th 2016

Regorafenib (Stivarga) improved overall survival versus best supportive care in patients with unresectable hepatocellular carcinoma who progressed after receiving sorafenib (Nexavar).

Wendy Setiawan on Pancreatic Cancer Incidence Across Ethnic Populations

May 2nd 2016

Wendy Setiawan, PhD, assistant professor of Preventive Medicine, Department of Preventive Medicine, Keck School of Medicine of University of Southern California, discusses a study that examined differences in pancreatic cancer incidence across five racial/ethnic populations in a multiethnic cohort.

Dr. Van Morris on Nivolumab as a Potential Treatment for Patients With Anal Cancer

May 2nd 2016

Van K. Morris, MD, assistant professor of GI Oncology, The University of Texas MD Anderson Cancer Center, discusses a study examining nivolumab (Opdivo) as a potential treatment for patients with anal cancer.

Sequencing Agents in Metastatic Colorectal Cancer

April 28th 2016

Use of VEGF-Targeted Tyrosine Kinase Inhibitors

April 28th 2016

Patient Selection for Aflibercept in Advanced CRC

April 28th 2016

The Hunt for Predictive Biomarkers

April 28th 2016

Ramucirumab Data for Colorectal Cancer: Where Does it Fit In

April 28th 2016

What Is Clinically Meaningful?

April 28th 2016

Reviewing Ramucirumab Data for Lung Cancer

April 28th 2016